KOSDAQ foreign investors’ 2trillion 5,000in net purchases, with biotech, API and clinical-trial issues also in focus
22~23 day on KOSDAQ, foreign investors 2 trillion 5,000 billion won worth of shares on a net basis. Reports said orders and earnings are rising following a capacity expansion at an active pharmaceutical ingredient manufacturer. D&D Pharmatech rose 14 percent amid expectations for the European Association for the Study of the Liver congress. GI Innovation rose 23 percent following the release of ASCO abstracts and reported an ORR of 40 percent in kidney cancer. Ingenia Therapeutics received approval for its preliminary listing review.
22 and 23, foreign investors were reported to have made net purchases worth 2 trillion 5,000 billion won in the stock market, focusing on KOSDAQ. The net purchases were reportedly concentrated in the semiconductor, robotics and biotech sectors.
Reports said the effects of capacity expansions are emerging in the active pharmaceutical ingredient industry. Orders have increased since the expansions, and the resulting performance indicators are said to have improved.
D&D Pharmatech’s share price rose 14 percent amid expectations for clinical results at the European Association for the Study of the Liver congress. Reports said expectations for the related presentation were reflected in the share price.
GI Innovation's share price rose following news of the ASCO abstract release, by 23%.40The company announced that the objective response rate (ORR) in the kidney cancer clinical trial of its immuno-oncology drug was %.
Korean-American biotechnology company Ingenia Therapeutics disclosed that it had received approval in its preliminary listing review. The disclosure stated that the approval had been granted to advance the listing process.
During this period, trading volume and share price fluctuations were substantial among related stocks. Each company prepared investor disclosures through the relevant disclosures and clinical results.